Sally Beauty Holdings, Inc. Announces EPS Growth and Positive Same Store Sales for the Fourth Quarter

Sally Beauty Holdings, Inc. Announces EPS Growth and Positive Same Store Sales for the Fourth Quarter

  • GAAP Diluted EPS Grows to $0.62; Increasing 6.9% Compared to Prior Year
  • Adjusted Diluted EPS Grows to $0.63; Increasing 8.6% Compared to Prior Year
  • Positive Same Store Sales Growth of +1.3% for Enterprise; +3.7% for Sally Beauty U.S. and Canada
  • E-commerce Sales Growth Continues: +69% Globally Compared to Prior Year
  • Gross Margin Sees Strong Expansion: Up 150 Basis Points Compared to Prior Year to 51.1%
  • Strong Cash Flow from Operations of $153 Million, Driven by Working Capital Improvements; Operating Free Cash Flow of $131 Million
  • $445 Million of Debt Reduction in Quarter, With Ample Liquidity Remaining; Balance Sheet Cash of $514 Million
  • Agile Reaction to COVID-19 and Continued Transformation Progress Provide Runway for FY21

DENTON, Texas–(BUSINESS WIRE)–Sally Beauty Holdings, Inc. (NYSE: SBH) (“the Company”) today announced financial results for its fourth quarter ended September 30, 2020. The Company will hold a conference call today at 7:30 a.m. Central Time to discuss these results.

Fiscal 2020 Fourth Quarter Overview

For the fourth quarter, consolidated same store sales increased by 1.3%. Consolidated net sales were $957.8 million in the fourth quarter, down 0.8% compared to the prior year, as an increase in same store sales, led by a +3.7% from the Sally Beauty U.S. and Canadian retail business, and a favorable impact from foreign currency translation of approximately 20 basis points on reported sales, was offset by a slower recovery from elements of Beauty Systems Group’s full-service business, the impact of lost professional sales associated with the second round of COVID-19 related shut-downs of California salons during parts of July and August, and a smaller store base with 23 fewer stores compared to the prior year. Global e-commerce sales grew by 69% in the fourth quarter compared to the prior year.

GAAP diluted earnings per share in the fourth quarter were $0.62, compared to $0.58 in the prior year, an increase of 6.9%, driven primarily by a much stronger gross margin rate, lower income tax expense, and a lower average share count; which was partially offset by modestly higher selling, general and administrative expenses due to higher e-commerce delivery expense and continued transformation investment, and an increase in interest expense. Adjusted diluted earnings per share, excluding charges related to the Company’s previously announced restructuring efforts in both years and COVID-19 related income in the current year from a Canadian wage subsidy, were $0.63 in the fourth quarter, compared to $0.58 in the prior year, an increase of 8.6%.

“During the fourth quarter, we saw a significant acceleration in our sales and margin performance compared to the third quarter boosted by the reopening and stabilization of our operations across the globe and progress from our strategic initiatives in innovation, digital content, technology and talent. While total reported sales for the fourth quarter slightly trailed the prior year period, due primarily to the ongoing impact of the COVID crisis and fewer stores, we are pleased to report positive same store sales and significant gross margin expansion. We ended the year with strong liquidity, including $131 million in operating free cash flow for the quarter and a strengthened balance sheet with over $500 million of cash after proactively reducing our debt levels by $445 million. I am proud of our 30,000 associates around the world who assisted our Company in meeting the needs of our customers during this unsettling time,” said Chris Brickman, president and chief executive officer.

“We begin fiscal 2021 focused on completing our transformation plan while maintaining stringent financial discipline and ample liquidity as uncertainty remains as to the duration and severity of the pandemic. Our strategic initiatives will involve capitalizing on strong consumer interest in DIY hair color, building and refining our digital customer experience including the addition of ‘Buy Online / Pickup In-Store’, growing our new Private Label Rewards Credit Card Program, expanding the rollout of JDA to the rest of our distribution centers, and growing our partnerships with Female-owned and Black-owned brands. This should provide our Company with a strong platform as we navigate past COVID-19 and achieve our goal of sustained long-term profitable growth.”

Update on Transformation Plan

Despite the disruptions caused by COVID-19, the Company completed key objectives of our Transformation Plan in Fiscal Year 2020, including:

  • The rollout of the Oracle-based point-of-sale system to both Sally Beauty and Beauty Systems Group stores;
  • The national launch of the new Sally Beauty brand campaign ‘Unleash Your PROtential’;
  • The launch of new service models including ‘Ship-From-Store’ at 2,400 Sally Beauty stores, ‘Same-Day Delivery’ at 1,000 Beauty Systems Group stores and ‘Curbside Pickup’ in both segments;
  • The launch of the new Private Label Rewards Credit Card Program at both Sally Beauty and Beauty Systems Group; and
  • The addition of key talent across store operations, merchandising, marketing, e-commerce and finance.

As we move into Fiscal Year 2021, the Company’s focus will be on the following key initiatives:

  • Leveraging elevated digital capabilities through the rollout of ‘Buy Online / Pickup In-Store’ at all Sally U.S. retail stores in November and expanding it to Beauty Systems Group stores in the second half of the year;
  • Growing customer engagement and loyalty through the recently launched Private Label Rewards Credit Card Program for the Sally Beauty segment and the new Beauty Systems Group loyalty framework, and redesigning of the Beauty Systems Group e-commerce site and mobile app;
  • Increasing brand partnerships that resonate strongly with our customers, including growing our leadership in Female-owned and Black-owned brands;
  • Optimizing efficiencies and driving savings through the ongoing rollout of JDA, our new merchandising and supply chain platform, to all distribution centers; and
  • Continuing to build and refine our digital customer experience, globally.

Fiscal 2020 Fourth Quarter Financial Detail

Consolidated gross profit for the fourth quarter was $489.1 million, an increase of $9.9 million from the prior year. Consolidated gross margin was 51.1%, an increase of 150 basis points compared to the prior year, driven primarily by fewer promotions and favorable mix shifts to higher margin categories, partially offset by a reduction in vendor allowances from fewer promotions and reduced inventory purchases.

As a percentage of sales, selling, general and administrative expenses were 38.3% compared to 37.7% in the prior year, driven primarily by higher e-commerce delivery expense, continued transformation investment, and a lower sales volume compared to the prior year.

GAAP operating earnings and operating margin in the fourth quarter were $119.7 million and 12.5%, respectively, compared to $116.1 million and 12.0%, respectively, in the prior year. Adjusted operating earnings and operating margin were $120.3 million and 12.6%, respectively, compared to $115.3 million and 11.9%, respectively, in the prior year.

GAAP net earnings in the fourth quarter were $70.2 million, an increase of $1.2 million, or 1.7% compared to the prior year. Adjusted EBITDA in the fourth quarter was $146.6million, an increase of $2.5 million, or 1.8%, compared to the prior year, and adjusted EBITDA margin was 15.3%, an increase of 40 basis points compared to the prior year.

During the fourth quarter, cash flow from operations was $152.5million, an increase of 30.8% compared to the prior year, driven in part by working capital improvements. Capital expenditures totaled $21.1million. Operating free cash flow was $131.4million, an increase of 66.6% compared to the prior year.

The Company used cash to reduce its debt levels by $445 million, including paying off its outstanding balance on its revolving line of credit of $375 million, the entire FILO loan balance of $20 million, and $50 million of the fixed portion of its Term Loan B. The Company did not repurchase any shares during the quarter. In addition, the Company also completed a small acquisition in Quebec, Canada, which added 10 stores, 17 direct sales consultants and exclusive distribution rights to premier professional hair color and hair care brands such as Wella Professional, Goldwell and Oribé.

At the end of the fourth quarter, the Company had $514 million in cash on the balance sheet and a zero balance on its $600 million revolving line of credit. Generally, the Company ended the quarter with a leverage ratio of 2.88x, reflecting our significant cash balance. For comparison purposes, the leverage ratio, as defined in our loan agreements, where the impact of cash on-hand is capped at $100 million for net debt calculation purposes, was 3.79x.

Fiscal 2020 Fourth Quarter Segment Results

Sally Beauty Supply

  • Global segment same store sales increased by 1.7% for the fourth quarter. The Sally Beauty businesses in the U.S. and Canada represented 80% of the segment sales for the quarter and had a same store sales increase of 3.7%. Europe had a decrease in same store sales for the quarter while Latin America had a significant decline in same store sales given approximately 15% of the stores were closed for more than half of the quarter due to COVID-19.
  • Net sales were $576.6 million in the quarter, an increase of 0.8% compared to the prior year, driven primarily by the increase in same store sales, a favorable foreign exchange impact of approximately 40 basis points, partially offset by 42 fewer stores compared to the prior year and the temporary store closures in Latin America due to COVID-19.
  • At the end of the quarter, net store count was 3,653, a decline of 42 stores compared to the prior year.
  • Gross margin increased by 180 basis points to 57.6% in the quarter with the Sally Beauty business in the U.S. and Canada hitting a gross margin of 61.0% for the first time. The positive impact from fewer promotions and favorable product mix were partially offset by lower vendor allowances.
  • GAAP operating earnings were $103.9 million in the quarter, an increase of 10.6% compared to the prior year. GAAP operating margin was 18.0%, compared to 16.4% in the prior year.

Beauty Systems Group

  • Total segment same store sales increased by 0.6% for the fourth quarter. The COVID-19 related shut-down of California salons had an unfavorable impact of approximately 90 basis points on the segment’s same store sales.
  • Net sales were $381.2 million in the quarter, a decrease of 3.3% compared to the prior year, driven primarily by a slower recovery from the national account chain business, the impact of lost sales associated with the second round of COVID-19 related shut-downs of California salons during parts of July and August, and an unfavorable foreign exchange impact of approximately 10 basis points.
  • At the end of the quarter, net store count was 1,385, an increase of 19 stores compared to the prior year.
  • Gross margin increased by 60 basis points to 41.2% in the quarter, driven primarily by fewer promotions but partially offset by lower vendor allowances.
  • GAAP operating earnings were $50.6 million in the quarter, a decrease of 14.4% compared to the prior year. GAAP operating margin in the quarter was 13.3%, compared to 15.0% in the prior year.
  • At the end of the quarter, there were 715 distributor sales consultants, compared to 748 in the prior year.

Fiscal 2020 Full-Year Financial Highlights

For the full fiscal year, consolidated same store sales decreased by 8.1%. Consolidated net sales were $3.51 billion, a decrease of 9.3%, driven primarily by the impact of COVID-19 shut-downs, operating 23 fewer stores, and an unfavorable impact from foreign currency translation of approximately 10 basis points. Global e-commerce sales grew by 103% compared to the prior year.

Full-year gross margin was 48.8%, a decrease of 50 basis points compared to the prior year. The primary drivers for the decline were from the non-cash write down of inventory of $27.1 million that occurred in the third quarter and lower vendor allowances from fewer promotions and reduced inventory purchases, which were mostly offset by the benefits of fewer promotions and the favorable mix shift to higher margin categories.

As a percentage of sales, selling, general and administrative expenses were 41.1% compared to 37.5% in the prior year, driven primarily by the significant deleveraging from lost sales related to COVID-19.

GAAP operating earnings and operating margin for the full fiscal year were $258.8 million and 7.4%, respectively, compared to $458.5 million and 11.8%, respectively, in the prior year. Adjusted operating earnings and operating margin, excluding COVID-19 net expenses in the current year and charges related to the Company’s transformation efforts in both years, were $294.4 million and 8.4%, respectively, compared to $457.8 million and 11.8%, respectively, in the prior fiscal year.

GAAP net earnings for the full fiscal year were $113.2 million, a decrease of $158.4 million, or 58.3%, from the prior year. Full-year Adjusted EBITDA was $438.5 million, a decrease of 23.7% from the prior year, and Adjusted EBITDA margin was 12.5%, a decline of approximately 230 basis points from the prior year.

GAAP diluted earnings per share for the full fiscal year were $0.99, a decline of 56.2% compared to the prior year. Adjusted diluted earnings per share in fiscal year 2020 were $1.22, a decline of 46.0% compared to the prior year.

For the full fiscal year, cash flow from operations was $426.9 million, an increase of 33.2% compared to the prior year, driven in part by working capital improvements. Net payments for capital expenditures totaled $110.8 million. Operating free cash flow was $316.1 million, an increase of 38.7% compared to the prior year. For the full fiscal year, the Company repurchased 4.7 million shares at an aggregate cost of $61.4 million.

Fiscal 2020 Full-Year Segment Results

Sally Beauty Supply

  • Global segment same store sales decreased by 8.1% for the full fiscal year, driven primarily by COVID-19 related store shutdowns. The Sally Beauty businesses in the U.S. and Canada represented 80% of the segment sales for the full fiscal year and had a decrease in same store sales of 6.5%.
  • Net sales were $2.08 billion for the full fiscal year, a decrease of 9.3% compared to the prior year, driven primarily by the disruption to business operations from COVID-19, 42 fewer stores, and an unfavorable foreign exchange impact of approximately 20 basis points.
  • Gross margin decreased by 110 basis points to 54.4% for the full fiscal year, driven primarily by the non-cash write down of inventory that occurred in the third quarter, lower vendor allowances from fewer promotions and reduced inventory purchases, which were partially offset by the benefits of fewer promotions and the favorable mix shift to higher margin categories.
  • GAAP operating earnings were $237.6 million for the full fiscal year, a decrease of 35.2% compared to the prior year, driven primarily by the impact from COVID-19. GAAP operating margin was 11.4% compared to 16.0% in the prior year.

Beauty Systems Group

  • Total segment same store sales decreased by 8.3% for the full fiscal year, driven primarily by the impact from COVID-19 related shutdowns.
  • Net sales were $1.43 billion for the full fiscal year, a decrease of 9.5% compared to the prior year, driven primarily by the disruption to business operations from COVID-19 and an unfavorable foreign currency translation impact of approximately 10 basis points.
  • Gross margin increased by 40 basis points at 40.7% for the full fiscal year, driven primarily by fewer promotions, which was partially offset by lower vendor allowances from fewer promotions and reduced inventory purchases.
  • GAAP operating earnings were $194.2 million for the full fiscal year, a decrease of 18.9% compared to the prior year, driven primarily by the impact of COVID-19. GAAP operating margin was 13.5% compared to 15.1% in the prior year.

Fiscal Year 2021 Outlook

The Company will provide perspective on its outlook for the coming quarters during its earnings conference call. The Company will not be providing formal guidance at this time.

Conference Call and Where You Can Find Additional Information

The Company will hold a conference call and audio webcast today to discuss its financial results and its business at approximately 7:30 a.m. Central Time. During the conference call, the Company may discuss and answer one or more questions concerning business and financial matters and trends affecting the Company. The Company’s responses to these questions, as well as other matters discussed during the conference call, may contain or constitute material information that has not been previously disclosed. Simultaneous to the conference call, an audio webcast of the call will be available via a link on the Company’s website, sallybeautyholdings.com/investor-relations. The conference call can be accessed by dialing (844) 867-6169 (International: (409) 207-6975) and referencing the access code 4004457#. The teleconference will be held in a “listen-only” mode for all participants other than the Company’s current sell-side and buy-side investment professionals. In addition, a supplemental slide presentation may be viewed during the call at the following link SBH Q4 Earnings Presentation. A replay of the earnings conference call will be available starting at 10:30 a.m. Central Time, November 12, 2020, through November 19, 2020, by dialing (866) 207-1041 (International: (402) 970-0847 and reference access code 4087901. Also, a website replay will be available on sallybeautyholdings.com/investor-relations.

About Sally Beauty Holdings, Inc.

Sally Beauty Holdings, Inc. (NYSE: SBH) is an international specialty retailer and distributor of professional beauty supplies with revenues of approximately $3.5 billion annually. Through the Sally Beauty Supply and Beauty Systems Group businesses, the Company sells and distributes through 5,038 stores, including 143 franchised units, and has operations throughout the United States, Puerto Rico, Canada, Mexico, Chile, Peru, the United Kingdom, Ireland, Belgium, France, the Netherlands, Spain and Germany. On average, Sally Beauty Supply stores offer about 8,000 products for hair color, hair care, skin care, and nails through proprietary brands such as Ion®, Generic Value Products®, Beyond the Zone® and Silk Elements® as well as professional lines such as Wella®, Clairol®, OPI®, Conair® and Hot Shot Tools®. On average, Beauty Systems Group stores, branded as Cosmo Prof or Armstrong McCall stores, along with its outside sales consultants, sell about 10,500 professionally branded products including Paul Mitchell®, Wella®, Matrix®, Schwarzkopf®, Kenra®, Goldwell®, Joico® and CHI®, intended for use in salons and for resale by salons to retail consumers. For more information about Sally Beauty Holdings, Inc., please visit sallybeautyholdings.com.

Cautionary Notice Regarding Forward-Looking Statements

Statements in this news release and the schedules hereto which are not purely historical facts or which depend upon future events may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, can be identified by the use of forward-looking terminology such as “believes,” “projects,” “expects,” “can,” “may,” “estimates,” “should,” “plans,” “targets,” “intends,” “could,” “will,” “would,” “anticipates,” “potential,” “confident,” “optimistic,” or the negative thereof, or other variations thereon, or comparable terminology, or by discussions of strategy, objectives, estimates, guidance, expectations and future plans. Forward-looking statements can also be identified by the fact these statements do not relate strictly to historical or current matters.

Readers are cautioned not to place undue reliance on forward-looking statements as such statements speak only as of the date they were made. Any forward-looking statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including, but not limited to, the risks and uncertainties related to COVID-19 and those described in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K for the year ended September 30, 2019, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and our Current Report on Form 8-K dated as of July 30, 2020, each as filed with the Securities and Exchange Commission. Consequently, all forward-looking statements in this release are qualified by the factors, risks and uncertainties contained therein. We assume no obligation to publicly update or revise any forward-looking statements.

Use of Non-GAAP Financial Measures

This news release and the schedules hereto include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the United States, or GAAP, and are therefore referred to as non-GAAP financial measures: (1) Adjusted EBITDA and EBITDA Margin; (2) Adjusted Operating Earnings and Operating Margin; (3) Adjusted Diluted Net Earnings Per Share; and (4) Operating Free Cash Flow. We have provided definitions below for these non-GAAP financial measures and have provided tables in the schedules hereto to reconcile these non-GAAP financial measures to the comparable GAAP financial measures.

Adjusted EBITDA and EBITDA Margin – We define the measure Adjusted EBITDA as GAAP net earnings before depreciation and amortization, interest expense, income taxes, share-based compensation, costs related to the Company’s previously announced restructuring plans, costs related to COVID-19, costs related to the non-cash write down of inventory related to slow moving SKUs and impairment costs related to long-lived assets not included in restructuring for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures. Adjusted EBITDA Margin is Adjusted EBITDA as a percentage of net sales.

Adjusted Operating Earnings and Operating Margin – Adjusted operating earnings are GAAP operating earnings that exclude costs related to the Company’s previously announced restructuring plans and costs related to COVID-19 for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures. Adjusted Operating Margin is Adjusted Operating Earnings as a percentage of net sales.

Adjusted Diluted Net Earnings Per Share – Adjusted diluted net earnings per share is GAAP diluted earnings per share that exclude tax-effected costs related to the Company’s previously announced restructuring plans and tax-effected costs related to COVID-19 for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures.

Operating Free Cash Flow – We define the measure Operating Free Cash Flow as GAAP net cash provided by operating activities less payments for capital expenditures (net). We believe Operating Free Cash Flow is an important liquidity measure that provides useful information to investors about the amount of cash generated from operations after taking into account payments for capital expenditures (net).

We believe that these non-GAAP financial measures provide valuable information regarding our earnings and business trends by excluding specific items that we believe are not indicative of the ongoing operating results of our businesses; providing a useful way for investors to make a comparison of our performance over time and against other companies in our industry.

We have provided these non-GAAP financial measures as supplemental information to our GAAP financial measures and believe these non-GAAP measures provide investors with additional meaningful financial information regarding our operating performance and cash flows. Our management and Board of Directors also use these non-GAAP measures as supplemental measures to evaluate our businesses and the performance of management, including the determination of performance-based compensation, to make operating and strategic decisions, and to allocate financial resources. We believe that these non-GAAP measures also provide meaningful information for investors and securities analysts to evaluate our historical and prospective financial performance. These non-GAAP measures should not be considered a substitute for or superior to GAAP results. Furthermore, the non-GAAP measures presented by us may not be comparable to similarly titled measures of other companies.

Supplemental Schedules

 

 

Segment Information

1

 

Non-GAAP Financial Measures Reconciliations

2-3

 

Non-GAAP Financial Measures Reconciliations; Adjusted EBITDA and

Operating Free Cash Flow

4

 

Store Count and Same Store Sales

5

 

SALLY BEAUTY HOLDINGS, INC. AND SUBSIDIARIES
Consolidated Statements of Earnings
(In thousands, except per share data)
(Unaudited)
   
 
Three Months Ended September 30, Twelve Months Ended September 30,

2020

2019

 

Percentage

Change

2020

2019

Percentage

Change

   
Net sales

$ 957,812

$ 965,937

 

(0.8)%

$ 3,514,330

$ 3,876,411

(9.3)%

Cost of products sold

468,669

486,646

 

(3.7)%

1,798,736

1,965,869

(8.5)%

Gross profit

489,143

479,291

 

2.1 %

1,715,594

1,910,542

(10.2)%

Selling, general and administrative expenses

366,982

363,955

 

0.8 %

1,442,809

1,452,751

(0.7)%

Restructuring

2,484

(756)

 

(428.6)%

14,025

(682)

(2156.5)%

Operating earnings

119,677

116,092

 

3.1 %

258,760

458,473

(43.6)%

Interest expense

28,310

22,217

 

27.4 %

98,793

96,309

2.6 %

Earnings before provision for income taxes

91,367

93,875

 

(2.7)%

159,967

362,164

(55.8)%

Provision for income taxes

21,179

24,868

 

(14.8)%

46,722

90,541

(48.4)%

Net earnings

$ 70,188

$ 69,007

 

1.7 %

$ 113,245

$ 271,623

(58.3)%

   
Earnings per share:  
Basic

$0.63

$0.58

 

8.6 %

$0.99

$2.27

(56.4)%

Diluted

$0.62

$0.58

 

6.9 %

$0.99

$2.26

(56.2)%

   
Weighted average shares:  
Basic

112,296

118,374

 

113,881

119,636

Diluted

113,090

118,997

 

114,680

120,283

 

Basis Point

Change

Basis Point

Change

Comparison as a percentage of net sales  
Consolidated gross margin

51.1%

49.6%

 

150

48.8%

49.3%

(50)

Selling, general and administrative expenses

38.3%

37.7%

 

60

41.1%

37.5%

360

Consolidated operating margin

12.5%

12.0%

 

50

7.4%

11.8%

(440)

   
Effective tax rate

23.2%

26.5%

 

(330)

29.2%

25.0%

420

   
 
SALLY BEAUTY HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
 
September 30,

2020

2019

 
Cash and cash equivalents

$ 514,151

$ 71,495

Trade and other accounts receivable

56,429

104,539

Inventory

814,503

952,907

Other current assets

48,014

34,612

Total current assets

1,433,097

1,163,553

Property and equipment, net

315,029

319,628

Operating lease asset

525,634

Goodwill and other intangible assets

598,321

592,837

Other assets

23,066

22,428

Total assets

$ 2,895,147

$ 2,098,446

 
Current maturities of long-term debt

$ 180

$ 1

Accounts payable

236,333

278,688

Accrued liabilities

170,665

169,054

Current operating lease liabilities

153,267

Income taxes payable

2,917

8,336

Total current liabilities

563,362

456,079

Long-term debt

1,796,897

1,594,542

Long-term operating lease liabilities

394,375

Other liabilities

32,976

27,757

Deferred income tax liabilities, net

92,094

80,391

Total liabilities

2,879,704

2,158,769

Total stockholders’ equity (deficit)

15,443

(60,323)

Total liabilities and stockholders’ equity (deficit)

$ 2,895,147

$ 2,098,446

 
Supplemental Schedule 1
 
SALLY BEAUTY HOLDINGS, INC. AND SUBSIDIARIES
Segment Information
(In thousands)
(Unaudited)
 
 
Three Months Ended September 30, Twelve Months Ended September 30,

 

2020

 

 

2019

 

Percentage

Change

 

2020

 

 

2019

 

Percentage

Change

Net sales:
Sally Beauty Supply (“SBS”)

$

576,578

 

$

571,856

 

0.8

%

$

2,080,703

 

$

2,293,094

 

(9.3

)%

Beauty Systems Group (“BSG”)

 

381,234

 

 

394,081

 

(3.3

)%

 

1,433,627

 

 

1,583,317

 

(9.5

)%

Total net sales

$

957,812

 

$

965,937

 

(0.8

)%

$

3,514,330

 

$

3,876,411

 

(9.3

)%

 
Operating earnings:
SBS

$

103,904

 

$

93,942

 

10.6

%

$

237,588

 

$

366,412

 

(35.2

)%

BSG

 

50,649

 

 

59,172

 

(14.4

)%

 

194,206

 

 

239,572

 

(18.9

)%

Segment operating earnings

 

154,553

 

 

153,114

 

0.9

%

 

431,794

 

 

605,984

 

(28.7

)%

 
Unallocated expenses (1)

 

32,392

 

 

37,778

 

(14.3

)%

 

159,009

 

 

148,193

 

7.3

%

Restructuring

 

2,484

 

 

(756

)

(428.6

)%

 

14,025

 

 

(682

)

(2156.5

)%

Interest expense

 

28,310

 

 

22,217

 

27.4

%

 

98,793

 

 

96,309

 

2.6

%

Earnings before provision for income taxes

$

91,367

 

$

93,875

 

(2.7

)%

$

159,967

 

$

362,164

 

(55.8

)%

 
 
Segment gross margin:

 

2020

 

 

2019

 

Basis Point

Change

 

2020

 

 

2019

 

Basis Point

Change

SBS

 

57.6

%

 

55.8

%

180

 

 

54.4

%

 

55.5

%

(110

)

BSG

 

41.2

%

 

40.6

%

60

 

 

40.7

%

 

40.3

%

40

 

 
Segment operating margin:
SBS

 

18.0

%

 

16.4

%

160

 

 

11.4

%

 

16.0

%

(460

)

BSG

 

13.3

%

 

15.0

%

(170

)

 

13.5

%

 

15.1

%

(160

)

Consolidated operating margin

 

12.5

%

 

12.0

%

50

 

 

7.4

%

 

11.8

%

(440

)

 
 
 
(1) Unallocated expenses, including share-based compensation expense, consist of corporate and shared costs and are included in selling, general and administrative expenses.
Supplemental Schedule 2
 
SALLY BEAUTY HOLDINGS, INC. AND SUBSIDIARIES
Non-GAAP Financial Measures Reconciliations
(In thousands, except per share data)
(Unaudited)
 
 

Three Months Ended September 30, 2020

As Reported Restructuring (1) COVID-19 (2)

As Adjusted

(Non-GAAP)

 
Selling, general and administrative expenses

$

366,982

 

$

 

$

1,872

 

$

368,854

 

SG&A expenses, as a percentage of sales

 

38.3

%

 

38.5

%

Operating earnings

 

119,677

 

 

2,484

 

 

(1,872

)

 

120,289

 

Operating margin

 

12.5

%

 

12.6

%

Earnings before provision for income taxes

 

91,367

 

 

2,484

 

 

(1,872

)

 

91,979

 

Provision for income taxes (3)

 

21,179

 

 

584

 

 

(502

)

 

21,261

 

Net earnings

$

70,188

 

$

1,900

 

$

(1,370

)

$

70,718

 

 
Earnings per share:
Basic

$

0.63

 

$

0.02

 

$

(0.01

)

$

0.63

 

Diluted

$

0.62

 

$

0.02

 

$

(0.01

)

$

0.63

 

 

Three Months Ended September 30, 2019

As Reported Restructuring (1)

As Adjusted

(Non-GAAP)

 
Selling, general and administrative expenses

$

363,955

 

$

 

$

363,955

 

SG&A expenses, as a percentage of sales

 

37.7

%

 

37.7

%

Operating earnings

 

116,092

 

 

(756

)

 

115,336

 

Operating margin

 

12.0

%

 

11.9

%

Earnings before provision for income taxes

 

93,875

 

 

(756

)

 

93,119

 

Provision for income taxes (3)

 

24,868

 

 

(277

)

 

24,591

 

Net earnings

$

69,007

 

$

(479

)

$

 

$

68,528

 

 
Earnings per share:
Basic

$

0.58

 

$

(0.00

)

$

0.58

 

Diluted

$

0.58

 

$

(0.00

)

$

0.58

 

 
 
 
 
(1) For the three months ended September 30, 2020, restructuring represents expenses incurred primarily in connection with Project Surge and the Transformation Plan. For the three months ended September 30, 2019, restructuring represents a gain in connection with the sale of our Marinette, Wisconsin, fulfillment center, partially offset by expenses incurred in connection with the 2018 Restructuring Plan.
 
(2) COVID-19 primarily represents a wage subsidy provided by the Canadian government under the Canada Emergency Wage Subsidy.
   
(3) The provision for income taxes was calculated using the applicable tax rates for each country, while excluding the tax benefits for countries where the tax benefit is not currently deemed probable of being realized.
Supplemental Schedule 3
 
SALLY BEAUTY HOLDINGS, INC. AND SUBSIDIARIES
Non-GAAP Financial Measures Reconciliations, Continued
(In thousands, except per share data)
(Unaudited)
 
 
Twelve Months Ended September 30, 2020
As Reported Restructuring (1) COVID-19 (2)

As Adjusted

(Non-GAAP)

 
Selling, general and administrative expenses

$

1,442,809

 

$

 

$

(21,578

)

$

1,421,231

 

SG&A expenses, as a percentage of sales

 

41.1

%

 

40.4

%

Operating earnings

 

258,760

 

 

14,025

 

 

21,578

 

 

294,363

 

Operating margin

 

7.4

%

 

8.4

%

Earnings before provision for income taxes

 

159,967

 

 

14,025

 

 

21,578

 

 

195,570

 

Provision for income taxes (3)

 

46,722

 

 

3,551

 

 

5,183

 

 

55,456

 

Net earnings

$

113,245

 

$

10,474

 

$

16,395

 

$

140,114

 

 
Earnings per share:
Basic

$

0.99

 

$

0.09

 

$

0.14

 

$

1.23

 

Diluted

$

0.99

 

$

0.09

 

$

0.14

 

$

1.22

 

 
Twelve Months Ended September 30, 2019
As Reported Restructuring (1)

As Adjusted

(Non-GAAP)

 
Selling, general and administrative expenses

$

1,452,751

 

$

 

$

1,452,751

 

SG&A expenses, as a percentage of sales

 

37.5

%

 

37.5

%

Operating earnings

 

458,473

 

 

(682

)

 

457,791

 

Operating margin

 

11.8

%

 

11.8

%

Earnings before provision for income taxes

 

362,164

 

 

(682

)

 

361,482

 

Provision for income taxes (3)

 

90,541

 

 

(573

)

 

89,968

 

Net earnings

$

271,623

 

$

(109

)

$

271,514

 

 
Earnings per share:
Basic

$

2.27

 

$

(0.00

)

$

2.27

 

Diluted

$

2.26

 

$

(0.00

)

$

2.26

 

 
 
 
 
(1) For fiscal year 2020, restructuring represents expenses incurred primarily in connection with Project Surge and the Transformation Plan. For fiscal year 2019, restructuring represents gains in connection with the sale of our secondary headquarters and certain fulfillment centers, partially offset by expenses incurred in connection with the 2018 Restructuring Plan.
 
(2) COVID-19 primarily represents costs associated with disaster pay for furloughed employees in response to the coronavirus pandemic. These cost were partially offset by an employee retention payroll tax credit provided by the U.S. Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, and the Canada Emergency Wage Subsidy provided by the Canadian government.
 
(3) The provision for income taxes was calculated using the applicable tax rates for each country upon the recognition of expenses or gains, while excluding the tax benefits for countries where the tax benefit is not currently deemed probable of being realized.
 
Supplemental Schedule 4
 
SALLY BEAUTY HOLDINGS, INC. AND SUBSIDIARIES
Non-GAAP Financial Measures Reconciliations, Continued
(In thousands)
(Unaudited)
 
 

Three Months Ended September 30,

Twelve Months Ended September 30,

Adjusted EBITDA:

2020

2019

Percentage

Change

2020

2019

Percentage

Change

 
Net earnings

$

70,188

 

$

69,007

 

1.7

%

$

113,245

 

$

271,623

 

(58.3

)%

Add:
Depreciation and amortization

 

25,950

 

 

27,233

 

(4.7

)%

 

106,779

 

 

107,658

 

(0.8

)%

Interest expense

 

28,310

 

 

22,217

 

27.4

%

 

98,793

 

 

96,309

 

2.6

%

Provision for income taxes

 

21,179

 

 

24,868

 

(14.8

)%

 

46,722

 

 

90,541

 

(48.4

)%

EBITDA (non-GAAP)

 

145,627

 

 

143,325

 

1.6

%

 

365,539

 

 

566,131

 

(35.4

)%

Inventory charges (1)

 

 

 

 

 

 

27,054

 

 

 

100.0

%

COVID-19

 

(1,872

)

 

 

100.0

%

 

21,578

 

 

 

100.0

%

Restructuring

 

2,484

 

 

(756

)

(428.6

)%

 

14,025

 

 

(682

)

(2156.5

)%

Share-based compensation

 

(668

)

 

1,452

 

(146.0

)%

 

8,426

 

 

9,180

 

(8.2

)%

Impairment (2)

 

982

 

 

 

100.0

%

 

1,883

 

 

 

100.0

%

Adjusted EBITDA (non-GAAP)

$

146,553

 

$

144,021

 

1.8

%

$

438,505

 

$

574,629

 

(23.7

)%

 

Basis Point

Change

Basis Point

Change

Adjusted EBITDA as a percentage of net sales
Adjusted EBITDA margin

 

15.3

%

 

14.9

%

40

 

 

12.5

%

 

14.8

%

(230

)

 
 
Operating Free Cash Flow:

2020

2019

Percentage

Change

2020

2019

Percentage

Change

Net cash provided by operating activities

$

152,505

 

$

116,592

 

30.8

%

$

426,889

 

$

320,415

 

33.2

%

Less:
Payments for property and equipment, net (3)

 

21,103

 

 

37,701

 

(44.0

)%

 

110,805

 

 

92,443

 

19.9

%

Operating free cash flow (non-GAAP)

$

131,402

 

$

78,891

 

66.6

%

$

316,084

 

$

227,972

 

38.7

%

 
(1) Incremental, non-cash write down of inventory as part of aggressive tactical inventory clearance actions.
 
(2) Impairment charges related to long-lived assets and operating lease assets outside of restructuring.
 
(3) For the three and twelve months ended September 30, 2019, payments for property and equipment, net includes cash proceeds of $3.3 million and $15.3 million, respectively, from the sale of our secondary headquarters and certain fulfillment centers in connection with the Transformation Plan.
Supplemental Schedule 5
 
SALLY BEAUTY HOLDINGS, INC. AND SUBSIDIARIES
Store Count and Same Store Sales
(Unaudited)
 
 
As of September 30,

2020

2019

Change

 
Number of stores:
SBS:
Company-operated stores

3,644

 

3,682

 

(38

)

Franchise stores

9

 

13

 

(4

)

Total SBS

3,653

 

3,695

 

(42

)

BSG:
Company-operated stores

1,251

 

1,220

 

31

 

Franchise stores

134

 

146

 

(12

)

Total BSG

1,385

 

1,366

 

19

 

Total consolidated

5,038

 

5,061

 

(23

)

 
Number of BSG distributor sales consultants

715

 

748

 

(33

)

 
BSG distributor sales consultants (DSC) include 183 and 202 sales consultants employed by our franchisees at September 30, 2020 and 2019, respectively. Additionally, the DSC count at September 30, 2020 includes 17 new DSCs in connection with a BSG acquisition.
Three Months Ended September 30, Twelve Months Ended September 30,

2020

2019

 

Basis Point

Change

2020

2019

Basis Point

Change

Same store sales growth (decline):
SBS

1.7

%

1.3

%

40

 

(8.1

)%

0.4

%

(850

)

BSG

0.6

%

0.8

%

(20

)

(8.3

)%

0.2

%

(850

)

Consolidated

1.3

%

1.1

%

20

 

(8.1

)%

0.3

%

(840

)

 
 
For the purpose of calculating our same store sales metrics, we compare the current period sales for stores open for 14 months or longer as of the last day of a month with the sales for these stores for the comparable period in the prior fiscal year. Our same store sales are calculated in constant U.S. dollars and include e-commerce sales, but do not generally include the sales from stores relocated until 14 months after the relocation. The sales from stores acquired are excluded from our same store sales calculation until 14 months after the acquisition.

 

Jeff Harkins

Investor Relations

940-297-3877

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Discount/Variety Women Other Retail Specialty Fashion Cosmetics Consumer Retail Online Retail

MEDIA:

Logo
Logo

SQZ Biotech to Present at November Virtual Investor Conferences

SQZ Biotech to Present at November Virtual Investor Conferences

WATERTOWN, Mass.–(BUSINESS WIRE)–
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ, and additional management will participate in the following upcoming virtual investor conferences:

Stifel 2020 Virtual Healthcare Conference

Tuesday, November 17, 2020

Presentation Time: 1:20 pm EST

Webcast available

Jefferies Virtual London Healthcare Conference

Thursday, November 19, 2020

Presentation Time: 7:55 am EST/12:55 pm GMT

Webcast available

The live webcast of SQZ’s presentations can also be accessed through the “Events & Presentations” page within the Investors & Media section of the SQZ website. Replays of the webcast will be available on the SQZ website for 90 days following the event.

About SQZ Biotech

SQZ Biotech is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the unique ability to deliver multiple materials into many patient cell types to engineer what we believe to be an unprecedented range of potential therapeutics for a range of diseases. SQZ has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays. Our goal is to use the SQZ approach to establish a new paradigm for cell therapies. The first therapeutic applications leverage SQZ’s ability to generate target-specific immune responses, both in activation for the treatment of solid tumors and immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases. For more information please visit www.sqzbiotech.com.

Forward Looking Statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including statements relating to upcoming events and presentations, our product candidates, preclinical or clinical trial timing, and preclinical or clinical data or results. These forward-looking statements are based on management’s current expectations. The words ”may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

These and other important factors discussed under the caption “Risk Factors” in our Form S-1 filed with the U.S. Securities and Exchange Commission (SEC) on October 26, 2020 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management’s estimates as of this date. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. While we may elect to update forward-looking statements in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.

Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this press release, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources.

SQZ IR Contact:

Rebecca Cohen

Corporate and Investor Relations

[email protected]

617-758-8672 ext. 728

Media Contact:

Kate Contreras

[email protected]

617-229-5960

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo

Express, Inc. Announces Earnings Release Date, Conference Call and Webcast for Third Quarter 2020 Results

Express, Inc. Announces Earnings Release Date, Conference Call and Webcast for Third Quarter 2020 Results

COLUMBUS, Ohio–(BUSINESS WIRE)–
Fashion apparel retailer Express, Inc. (NYSE: EXPR) today announced that it will conduct a conference call to discuss third quarter 2020 results on Thursday, December 3, 2020 at 8:30 a.m. Eastern Time (ET). Earlier that morning, the Company will issue a press release detailing those results. The conference call will be hosted by Tim Baxter, Chief Executive Officer, and Perry Pericleous, Senior Vice President and Chief Financial Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201112005078/en/

Express storefront at Easton Town Center in Columbus, Ohio. (Photo: Business Wire)

Express storefront at Easton Town Center in Columbus, Ohio. (Photo: Business Wire)

Investors and analysts interested in participating in the call are invited to dial (877) 683-0508 approximately ten minutes prior to the start of the call. The conference call will also be webcast live at http://www.express.com/investor and remain available for 90 days. A telephone replay of this call will be available at 12:00 p.m. ET on December 3, 2020 until 11:59 p.m. ET on December 10, 2020 and can be accessed by dialing (800) 585-8367 and entering the replay pin number 8242308. In addition, an investor presentation of third quarter 2020 results will be available at http://www.express.com/investor at approximately 7:00 a.m. ET on December 3, 2020.

About Express, Inc.:

Express is a modern, versatile, dual gender apparel and accessories brand that helps people get dressed for every day and any occasion. Launched in 1980 with the idea that style, quality and value should all be found in one place, Express has always been a brand of the now, offering some of the most important and enduring fashion trends. Express aims to Create Confidence & Inspire Self-Expression through a design & merchandising view that brings forward The Best of Now for Real Life Versatility.

The company operates over 500 retail and factory outlet stores in the United States and Puerto Rico, as well as an online store. Express, Inc. is traded on the NYSE under the symbol EXPR. For more information, please visit www.express.com.

Investor Contact:

Dan Aldridge

[email protected]

(614) 474-4890

Media Contact:

Alysa Spittle

[email protected]

(614) 474-4745

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Men Online Retail Other Retail Family Discount/Variety Specialty Consumer Fashion Teens Retail Other Consumer Women

MEDIA:

Photo
Photo
Express storefront at Easton Town Center in Columbus, Ohio. (Photo: Business Wire)

TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

– Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20

– Additional clinical sites to include UCSF Medical Center and Princess Margaret Cancer Centre in the TC-210 Phase 1/2 clinical trial

– Agreement with ElevateBio for additional manufacturing capacity for production of TC-210 Phase 2 clinical trial material

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.

“The third quarter was marked by consistency in the clinical benefit provided by our lead TRuC-T cell program, TC-210, previously shown to have produced RECIST partial responses at its very first dose level, as well as the completion of a successful financing,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. “As we prepare for the expansion portion of the TC-210 trial, we are excited to bring on additional clinical sites to increase patient recruitment and we have also launched a strategic partnership with ElevateBio, whose state-of-the-art manufacturing center will support the Phase 2 clinical trial of TC-210 and planned investigator-initiated studies. We look forward to providing a clinical data update on TC-210 in the fourth quarter.”

Recent Developments

  • TCR2 announced a partnership with ElevateBio, LLC, a Cambridge, MA-based creator and operator of a portfolio of innovative cell and gene therapy companies. The agreement with ElevateBio provides TCR2 access to ElevateBio BaseCamp, its centralized 140,000 square foot, world-class cell and gene therapy manufacturing facility based in Waltham, MA. The BaseCamp partnership enables TCR2 Therapeutics to establish additional manufacturing capacity and technical capabilities in the U.S., in addition to its existing Stevenage, UK, manufacturing facility, and will support the Phase 2 expansion portion of the TC-210 Phase 1/2 clinical trial once a recommended Phase 2 dose is defined.

Anticipated Milestones

  • TCR2 anticipates an interim update from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in 4Q20.
  • TCR2 anticipates an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in 2021.
  • TCR2 anticipates certification of its manufacturing facility in Stevenage, UK, in 4Q20.
  • TCR2 anticipates an IND filing for a third TRuC-T cell program in 2021.

Financial Highlights

  • Cash Position: TCR2 ended the third quarter of 2020 with $246.7 million in cash, cash equivalents, and investments compared to $158.1 million as of December 31, 2019. Net cash used in operations was $10.8 million for the third quarter of 2020 compared to $10.1 million for third quarter of 2019. TCR2 projects net cash use of $65-70 million for 2020.

  • R&D Expenses: Research and development expenses were $12.8 million for the third quarter of 2020 compared to $11.3 million for the third quarter of 2019. The increase in R&D expenses were primarily related to increases in headcount, activities related to the Phase 1/2 clinical trial of TC-210 and activities related to the Phase 1/2 clinical trial of TC-110.

  • G&A Expenses: General and administrative expenses were $4.4 million for the third quarter of 2020 compared to $3.5 million for the third quarter of 2019. The increase in general and administrative expenses was primarily due to an increase in personnel costs and costs associated with operations as a public company.

  • Net Loss: Net loss was $16.9 million for the third quarter of 2020 compared to $13.8 million for the third quarter of 2019, driven predominantly by increased personnel expenses.

Upcoming Events

TCR2 Therapeutics management is scheduled to participate at the following upcoming conferences.

  • Jefferies Virtual London Healthcare Conference: Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics, will provide a company update using a virtual platform on Wednesday, November 18, 2020 at 9:40am ET
  • Piper Sandler 32nd Annual Virtual Healthcare Conference: Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, and Alfonso Quintás Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics, will participate in a fireside chat using a virtual platform on Monday, November 23, 2020 at 10:00am ET

Forward-looking Statements

This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding the therapeutic potential of TC-210, timing for interim updates for the TC-210 and TC-110 clinical trials, timing for the certification of our manufacturing facility in Stevenage, UK, increased manufacturing capacity and technical capabilities, including relating to our manufacturing partnership with ElevateBio, LLC, increased clinical trial demand, future IND filings and clinical development plans, the development of the Company’s TRuC-T cells, their potential characteristics, applications and clinical utility, and the potential therapeutic applications of the Company’s TRuC-T cell platform.

The expressed or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR2’s ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, including TCR2’s ability to secure additional manufacturing facilities; whether TCR2‘s cash resources will be sufficient to fund TCR2‘s foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR2’s ongoing operations; and other risks set forth under the caption “Risk Factors” in TCR2’s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although TCR2 believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.

Moreover, except as required by law, neither TCR2 nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

About TCR

2

Therapeutics

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR2 Therapeutics Inc.
(617) 949-5667
[email protected]

TCR

2

THERAPEUTICS INC.

UNAUDITED CONSOLIDA
TED BALANCE SHEETS

(amounts in thousands, except share data)

    September
 
30, 2020
  December
 
31, 2019
 
Assets              
Current assets              
Cash and cash equivalents   $ 101,614   $ 65,296  
Investments     145,109     92,828  
Prepaid expenses and other current assets     7,509     5,061  
Total current assets     254,232     163,185  
               
Property and equipment, net     6,201     4,926  
Restricted cash     417     417  
Deferred offering costs          
Total assets   $ 260,850   $ 168,528  
               
Liabilities and stockholders

equity
             
Accounts payable   $ 2,948   $ 2,483  
Accrued expenses and other current liabilities     4,904     5,050  
Total current liabilities     7,852     7,533  
               
Other liabilities     635     546  
Total liabilities     8,487     8,079  
               
Stockholders’ equity              
Common stock, $0.0001 par value; 150,000,000 shares authorized; 33,397,669 and 24,050,936 shares issued; 33,380,211 and 23,981,109 shares outstanding at September 30, 2020 and December 31, 2019, respectively.     3     2  
Additional paid-in capital     483,433     342,896  
Accumulated other comprehensive income     191     142  
Accumulated deficit     (231,264 )   (182,591 )
Total stockholders’ equity     252,363     160,449  
Total liabilities and stockholders’ equity   $ 260,850   $ 168,528  

TCR

2

THERAPEUTICS INC.

UNAUDITED CONSOLIDATED S
TATEMENTS OF OPERATIONS

(amounts in thousands, except share and per share data)

    Three Months Ended

September
 
30,
    Nine Months Ended

September
 
30,
 
    2020     2019     2020     2019  
Operating expenses                                
Research and development   $ 12,820     $ 11,374     $ 37,682     $ 28,096  
General and administrative     4,371       3,522       12,451       9,715  
Total operating expenses     17,191       14,896       50,133       37,811  
Loss from operations     (17,191 )     (14,896 )     (50,133 )     (37,811 )
                                 
Interest income, net     300       1,090       1,546       3,039  
Loss before income taxes     (16,891 )     (13,806 )     (48,587 )     (34,772 )
                                 
Income taxes     31             86        
Net loss     (16,922 )     (13,806 )     (48,673 )     (34,772 )
                                 
Accretion of redeemable convertible preferred stock to redemption value                     $ (49,900 )
Net loss attributable to common stockholders   $ (16,922 )   $ (13,806 )   $ (48,673 )   $ (84,672 )
                                 
Per share information                                
Net loss per share of common stock, basic and diluted   $ (0.56 )   $ (0.58 )   $ (1.86 )   $ (4.21 )
                                 
Weighted average shares outstanding, basic and diluted     30,340,355       23,874,593       26,158,040       20,125,955  

TCR

2

THERAPEUTICS INC.

UNAUDITED CONSOLIDATED S
TATEMENTS OF CASH FLOWS

(amounts in thousands)

  Nine Months Ended September
 
30,
 
  2020     2019  
Operating activities              
Net loss $ (48,673 )   $ (34,772 )
Adjustments to reconcile net loss to cash used in operating activities:              
Depreciation and amortization   1,114       558  
Stock-based compensation expense   6,186       4,597  
Deferred tax liabilities   86        
Changes in operating assets and liabilities:              
Prepaid expenses and other current assets   (2,449 )     (3,615 )
Accounts payable   610       489  
Accrued expenses and other liabilities   (114 )     1,697  
Cash used in operating activities   (43,240 )     (31,046 )
               
Investing activities              
Purchases of equipment   (2,523 )     (3,060 )
Purchases of investments   (162,147 )     (126,534 )
Proceeds from sale or maturity of investments   109,916       82,990  
Cash used in investing activities   (54,754 )     (46,604 )
               
Financing activities              
Proceeds from public offering of common stock, net of issuance costs   133,570       79,121  
Proceeds from the exercise of stock options   742       299  
Cash provided by financing activities   134,312       79,420  
               
Net change in cash, cash equivalents, and restricted cash   36,318       1,770  
Cash, cash equivalents, and restricted cash at beginning of year   65,713       47,964  
Cash, cash equivalents, and restricted cash at end of period $ 102,031     $ 49,734  

Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases

BERWYN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced it successfully completed the dog cohort of a chronic toxicology study of its lead therapeutic compound ANVS401 for the treatment of AD and PD, reporting no negative side effects.

The nine-month dog study was part of a series of animal toxicology studies, funded by a $1.9 million grant from the National Institutes of Health that began in the fourth quarter of 2019. The strong safety data corroborates the positive results from the Company’s prior one-month safety studies in mice, rats, dogs, and humans and six-month study in rats.   

Maria Maccecchini, Ph.D., CEO, commented, “The strong safety profile observed in ANVS401 in our chronic tox study in dogs is another important milestone for Annovis. Our chronic toxicology studies, which are key to enabling us to conduct long-term human studies, provide a solid foundation for ANVS401 as we continue to recruit and treat patients for our two active Phase 2a clinical trials. We intend to report interim data on our Phase 2a clinical trials in the first quarter of 2021.”

About
Annovis
Bio

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the company’s website: www.annovisbio.com.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
[email protected]

SOURCE: Annovis Bio, Inc.

Energizer Holdings, Inc. Announces CEO Succession

– Alan R. Hoskins to Retire as CEO in January 2021

– Board Elects Mark S. LaVigne as Successor

PR Newswire

ST. LOUIS, Nov. 12, 2020 /PRNewswire/ — Energizer Holdings, Inc. (NYSE: ENR) (the “company”) today announced that Alan R. Hoskins has informed the company’s Board of Directors of his decision to retire as Chief Executive Officer, effective January 1, 2021. The Board has elected Mark S. LaVigne, President and Chief Operating Officer of Energizer, to succeed Mr. Hoskins as the company’s next CEO. Mr. Hoskins will continue to serve as a Director, upon election at the 2021 Annual Shareholders’ Meeting, and as an advisor to the company until September 30, 2021. The Board intends to nominate Mr. LaVigne to stand for election as a Director at the 2021 Annual Shareholders’ Meeting.  

“Alan is an exceptional leader who has guided Energizer through an extraordinary transformation into a stand-alone public company and a global consumer products leader with a strong foundation for long-term success,” said Pat Moore, independent Chairman of the Board. “He has had a notable nearly four-decade-long career at our company, and during his time as CEO, has led the Energizer team through two strategic acquisitions and in building enduring brands, a global infrastructure and strong supplier and customer relationships. With his relentless focus on innovation, operations and people, Alan has helped develop a talented leadership team that is focused on delivering on Energizer’s strategic priorities. I’m pleased that he will remain as a Director and an advisor to the company through September to help ensure a smooth transition while he turns towards his personal philanthropic activities.”

Mr. Hoskins commented, “Like many people, over the past several months, I have had the opportunity to reflect on my life, my future and what is most important to me. After a fulfilling career at Energizer spanning nearly 40 years, including the last five as CEO, I determined in conjunction with the Board that now is the right time for Energizer to transition to new leadership. Mark’s capabilities and deep understanding of Energizer’s diverse markets, operations and colleagues make him uniquely qualified to lead Energizer into its next phase of growth. As I enter my next chapter, I look forward to spending more time with my family and pursuing philanthropic opportunities. I would like to thank all of our colleagues for their dedication and efforts in positioning Energizer as the leader in consumer products that it is today, especially through the recent challenges of the pandemic, and I am certain that Mark and the rest of the executive team will continue the company’s momentum for many years to come.”

Mr. Moore continued, “Mark’s appointment is the culmination of rigorous succession planning by the Board and we have great confidence that he will be an excellent CEO for Energizer. Mark is an outstanding executive who has helped define and execute Energizer’s strategic initiatives and has overseen the company’s integrated operating model with a focus on growing its platform and market positions in the Batteries, Lights and Auto Care categories. Through his time this past year serving as President and COO, along with his previous roles at Energizer and outside our organization, Mark brings strong leadership skills and expertise that will serve the company well into the future.”

“I am honored to take on the role of CEO and lead Energizer and its dedicated colleagues around the world,” said Mr. LaVigne. “Despite the unprecedented challenges of this year, our long-term strategies remain intact, and we are well-positioned to strengthen our leadership across categories and generate sustainable growth. We recognize we have hurdles to overcome, but I have complete confidence in our organization and am tremendously excited about Energizer’s future prospects. I thank Alan for his leadership and collaboration and look forward to working with him to ensure a seamless transition.”

Mr. Hoskins’ retirement concludes a remarkable, nearly four-decade-long career with Energizer, including serving as CEO since 2015. He has played a key role in the company’s growth and transformation, establishing Energizer as a standalone public company and defining its strategic priorities – leading with innovation, operating with excellence and driving productivity – as well as overseeing the company’s two transformational acquisitions of Spectrum Brands’ battery and portable lighting and global auto care businesses. Over the course of Mr. Hoskins’ tenure, Energizer has transformed into a leading global consumer products company and is now the global value share leader in the battery and auto care categories and the branded share leader in the portable lighting category. Mr. Hoskins’ focus on talent and culture as the key drivers of the company’s success has empowered colleagues to take control, drive significant change and deliver on commitments, as well as instilled diversity as a key value across the organization, with almost half of the Company’s critical roles now held by women and people of color. As a result of these efforts, Energizer has delivered strong financial results under Mr. Hoskins’ leadership, including five consecutive years of organic sales growth and significant Net Sales, Adjusted EBITDA and Adjusted Free Cash flow growth over the same timeframe, and is well positioned to generate long-term shareholder value for years to come.

Fourth Quarter and Fiscal Year 2020 Results

The company also announced today in a separate press release its fourth quarter and fiscal year 2020 results. The webcast is scheduled to begin at 10:00 a.m. ET and can be accessed at www.energizerholdings.com, under the “Investors” and “Events and Presentations” tabs. A replay of the webcast will be available on the company’s website.

About Energizer Holdings, Inc.

Energizer Holdings, Inc. (NYSE: ENR), headquartered in St. Louis, Missouri, is one of the world’s largest manufacturers and distributors of primary batteries, portable lights, and auto care appearance, performance, refrigerant, and fragrance products. Our portfolio of globally recognized brands include Energizer®, Armor All®, Eveready®, Rayovac®, STP®, Varta®, A/C Pro®, Refresh Your Car! ®, California Scents®, Driven®, Bahama & Co. ®, LEXOL®, Eagle One®, Nu Finish®, Scratch Doctor®, and Tuff Stuff®. As a global branded consumer products company, Energizer’s mission is to lead the charge to deliver value to our customers and consumers better than anyone else.

Forward-Looking Statements

Certain information contained in this news release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future results or performance and involve certain risks, uncertainties and assumptions difficult to predict or beyond our control. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on November 19, 2019 and subsequent Commission filings. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement to reflect the impact of circumstances or events that arise after the date the forward-looking statement was made. 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/energizer-holdings-inc-announces-ceo-succession-301171662.html

SOURCE Energizer Holdings, Inc.

Multifamily Portfolio in Hollywood, Los Angeles Trades Hands, Sale Facilitated by Walker & Dunlop

PR Newswire

BETHESDA, Md., Nov. 12, 2020 /PRNewswire/ — Walker & Dunlop, Inc. announced today that it completed the sale of Argyle & Harvard Apartments, a two-property, 98-unit value-add portfolio. Situated in the Hollywood submarket of Los Angeles, California, the unofficial global headquarters for the entertainment and media industry, the multifamily communities offer immediate access to Hollywood’s expanding corporate footprint and growing job base. It is estimated that over 566,000 jobs exist throughout neighboring submarkets, which include notable employers such as Netflix, HBO, ViacomCBS, and Showtime, as well as rapidly growing digital media startups.

Built in 1970 and 1955 respectively, Argyle & Harvard Apartments presents new ownership with the opportunity to significantly increase rental income. Enhancing finishes in the 21 lightly-renovated units, as well as fully renovating the 77 units that are in original condition, could result in an almost 44 percent increase in rents.

Walker & Dunlop’s Blake Rogers, Alexandra Caniglia, Hunter Combs, Javier Rivera, and Kevin Sheehan represented the seller and facilitated the sale of the portfolio.

The transaction is one of just seven multifamily property sales with 50+ units in the City of Los Angeles since the Covid-19 pandemic started; this represents more than a 50 percent decrease in transaction volume compared to the past several years1.

The Southern California Walker & Dunlop team has closed more than $325,000,000 in multifamily sales transactions over the past 30 days. Nationally, the Walker & Dunlop investment sales platform has also achieved dramatic growth with over $4 billion in sales volume completed through 3Q 2020 in the face of the pandemic. Walker & Dunlop is a top-ranked commercial real estate finance company; in 2019, the firm completed $32.0 billion in total transaction volume, and was ranked the #1 Fannie Mae DUS® multifamily lender and the #3 Freddie Mac Optigo® lender by volume.

For information about Walker & Dunlop’s view on the apartment market, including expert perspectives on markets, leadership, and the road ahead, visit our Driven by Insight information center.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD), headquartered in Bethesda, Maryland, is one of the largest commercial real estate finance companies in the United States. The company provides a comprehensive range of capital solutions for all commercial real estate asset classes, as well as investment sales brokerage services to owners of multifamily properties. Walker & Dunlop is included on the S&P SmallCap 600 Index and was ranked as one of FORTUNE Magazine’s Fastest Growing Companies in 2014, 2017, and 2018. Walker & Dunlop’s 900+ professionals in 40 offices across the nation have an unyielding commitment to client satisfaction.

1CoStar

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/multifamily-portfolio-in-hollywood-los-angeles-trades-hands-sale-facilitated-by-walker–dunlop-301171448.html

SOURCE Walker & Dunlop, Inc.

Akerna Corp. Reports Quarter Ended September 2020 Results

Total software ARR up 44%, software revenue up 40%, revenue up 16%, compared to the quarter ended September 2019.

PR Newswire

DENVER, Nov. 12, 2020 /PRNewswire/ — Akerna (Nasdaq: KERN), an enterprise software, leading compliance technology provider and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), today announced financial results for its quarter ended September 30, 2020.

“I’m thrilled to report we achieved 40% year over year software revenue growth in this quarter and have increased our total SaaS ARR by 44% over this same time last year,” said Jessica Billingsley, CEO of Akerna. “Looking forward, we are entering a period of massive market expansion.  Five new states have approved cannabis via ballot measure in the recent election potentially representing approximately $18M in new TAM for our software and services offerings, and many more states and countries have legislative initiatives proposed over the coming months. Our scaled ecosystem is uniquely positioned to capture these opportunities, with the most robust cannabis technology suite available.”

September Quarter 2020 Financial Highlights

  • Software revenue was $3.2 million, an increase of 40% year over year
  • Total revenue was $3.7 million, an increase of 16% year over year
  • Gross Profit was $2.0 million, an increase of 9% year over year
  • Net Loss was $4.7 million compared to a net loss of $2.3 million for the period ended September 30, 2019
  • Adjusted EBITDA was ($3.0 million), compared to ($2.2 million) for the period ended September 30, 2019
    • See “Explanation of Non-GAAP Financial Measures” below
  • Cash was $14.3 million as of September 30, 2020

September Quarter 2020 Key Metrics

  • Total SaaS ARR of $14.1 million, up 44% year over year
  • Average new MJ Platform order up 94% year over year
  • MJ Platform transaction volume up 181% year over year
  • Retail order volume up 68% year over year
  • Retail order value up 127% year over year
  • New Bookings ARR of $1.2 million

September Quarter 2020 Operational Highlights

  • Close the acquisition of Ample Organics
  • Signed an agreement with Priority Technology Holdings, Inc. to provide CBD and Hemp retailers that use Akerna’s Point of Sale products with a credit card payment processing solution
  • Launched MJ Retail, a first-of-its-kind proprietary software technology designed to provide merchants and consumers with a flexible and mobile-friendly experience offering a clean and lightweight Point of Sale solution that connects to the Akerna eco-system and which can leverage our Priority payments partnership
  • Announced the release of MJ Analytics, a next generation cannabis data analytics platform made possible through a partnership with the Business Intelligence firm Domo
  • Akerna consulting clients won 100% of the medical cannabis dispensary licenses awarded in Iowa
  • Closed a $12 million follow on offering

Conference Call Details

The Company will host a conference call Thursday November 12, 2020 at 8:30am ET to discuss its financial results and business highlights.  A question and answer session will follow prepared remarks. 

To participate in the conference call, please dial 877-407-3982 (domestic) or 201-493-6780 (international). Participants should request the Akerna Corp. Earnings Call or provide confirmation code 13713080.  Please dial into the call at least five minutes before the scheduled start time.

A replay of the call will be available through November 26, 2020, at (844) 512-2921 (domestic) or (412) 317-6671 (international). The passcode for the call and replay is 13713080.

About Akerna

Akerna is a global regulatory compliance technology company. Akerna’s service offerings include MJ Platform®, Leaf Data Systems®, solo sciences tech platform and Ample Organics. Since its establishment in 2010, Akerna has tracked more than $20 billion in cannabis sales. Akerna is based in Denver. For more information, please visit www.akerna.com and follow us on Twitter @AkernaCorp.

Forward Looking Statements

Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Such forward-looking statements include but are not limited to statements regarding our belief that recently passed ballot measures potentially represent approximately $18M in new TAM for our software and services offerings, having a scaled ecosystem gives us more opportunities to leverage these new markets and management’s conference call in relation to our quarterly results. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of significant known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside Akerna’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others that may affect actual results or outcomes, include (i) Akerna’s ability to maintain relationships with customers and suppliers and retain its management and key employees, (ii) changes in applicable laws or regulations, (iii) changes in the market place due to the coronavirus pandemic or other market factors, (iv) and other risks and uncertainties disclosed from time to time in Akerna’s filings with the U.S. Securities and Exchange Commission, including those under “Risk Factors” therein.  You are cautioned not to place undue reliance on forward-looking statements. All information herein speaks only as of the date hereof, in the case of information about Akerna, or the date of such information, in the case of information from persons other than Akerna. Akerna undertakes no duty to update or revise the information contained herein. Forecasts and estimates regarding Akerna’s industry and end markets are based on sources believed to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.

Explanation of Non-GAAP Financial Measures:

In addition to our results determined in accordance with U.S. generally accepted accounting principles (“GAAP”), we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP.

Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.  We attempt compensate for these limitations by providing specific information regarding the GAAP items excluded from these non-GAAP financial measures.

Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.


Adjusted EBITDA

We believe that Adjusted EBITDA, when considered with the financial statements determined in accordance with GAAP, is helpful to investors in understanding our performance and allows for comparison of our performance and credit strength to our peers. Adjusted EBITDA should not be considered alternatives to net loss as determined in accordance with GAAP as indicators of our performance or liquidity.

We define EBITDA as net loss before interest expense, provision for income taxes, depreciation and amortization, and change in fair value of convertible notes. We calculate Adjusted EBITDA as EBITDA further adjusted to exclude the effects of the following items for the reasons set forth below:

  • Stock-based compensation expense, because this represents a non-cash charge and our mix of cash and share-based compensation may differ from other companies, which effects the comparability of results of operations and liquidity;
  • Cost incurred in connection with business combinations that are required to be expensed as incurred in accordance with GAAP, because business combination related costs are specific to the complexity and size of the underlying transactions as well as the frequency of our acquisition activity these costs are not reflective of our ongoing operations
  • Costs incurred in connection with debt issuance when we elect the fair value option to account for the debt instrument because if we had not elected the fair value option such costs would be recognized as an adjustment to the effective interest and excluded from EBITDA
  • Restructuring costs because we believe these costs are not representative of operating performance; and
  • Equity in earnings (losses) of investees because our share of the operations of investees is not representative of our own operating performance and may not be monetized for a number of years.


Related Non-GAAP Expense Measures

We reference in our earnings call certain non-GAAP expense measures, including non-GAAP Operating Expenses, non-GAAP Operating Expenses excluding Ample, non-GAAP Product Development Expense, non-GAAP Sales and Marketing Expenses, non-GAAP Sales and Marketing Expenses excluding Ample, non-GAAP General and Administrative Expenses and non-GAAP General and Administrative Expenses excluding Ample. We believe that these non-GAAP financial measures, when considered with the financial statements determined in accordance with GAAP, are helpful to management and investors in understanding our performance quarter over quarter and to the comparable quarter in our prior fiscal year by excluding the same items we exclude from EBITDA to derive Adjusted EBITDA, as set forth above (stock-based compensation expense, costs incurred with business combinations, costs incurred in connection with debt issuance, and restructuring costs) for the same reasons stated above–  principally, that these expenses are not, in management’s opinion, easily comparable across reporting periods, are not reflective of ongoing operations and/or are not representative of our operating performance—and excluding the operational results of Ample, which we acquired in July 2020.   

We define non-GAAP Operating Expenses, non-GAAP Product Development Expense,  non-GAAP Total Sales and Marketing Expenses and non-GAAP General and Administrative Expenses as, in each case, the corresponding GAAP financial measure (Operating Expenses, Product Development Expense, Sales and Marketing Expenses and General and Administrative Expenses) excluding that portion of stock-based compensation expense, costs incurred with business combinations, costs incurred in connection with debt issuance, and restructuring costs that is attributable to that specific GAAP financial measure.

We define non-GAAP Operating Expenses excluding Ample, non-GAAP Product Development Expense excluding Ample,  non-GAAP Total Sales and Marketing Expenses excluding Ample and non-GAAP General and Administrative Expenses excluding Ample as, in each case, the relevant non-GAAP expense measure as calculated above with the additional exclusion of expenses contained in the expense measure attributable to our recently acquire subsidiary Ample Organics Inc.    

None of these non-GAAP expense measures should not be considered alternatives to the corresponding GAAP financial measures as determined in accordance with GAAP as indicators of our performance or liquidity.  Please review the tables provided below, for a reconciliation of each of these non-GAAP expense measures to the corresponding GAAP financial measure.

 


AKERNA CORP.


 

Condensed Consolidated Balance Sheets


(unaudited)


September 30,


June 30,


2020


2020


Assets

Current assets: 

Cash

$

14,257,858

$

24,155,828

Restricted cash

500,000

500,000

Accounts receivable, net

2,799,225

1,861,534

Prepaid expenses and other current assets

1,475,613

1,215,341

Total current assets

19,032,696

27,732,703

Non-current assets:

Fixed assets, net

1,395,690

131,095

Investment, net

244,774

246,308

Capitalized software, net

3,389,646

2,629,304

Intangible assets, net

10,730,021

7,493,975

Goodwill

46,500,030

20,254,309

Other non-current assets

41,925

41,925

Total Assets

$

81,334,782

$

58,529,619


Liabilities and Equity

Current liabilities

Accounts payable and accrued liabilities

$

5,998,001

$

4,861,928

Contingent consideration payable

817,000

389,000

Deferred revenue 

1,170,625

368,685

Current portion of long-term debt

10,146,001

6,135,364

Total current liabilities

18,131,627

11,754,977

Long-term debt, less current portion

5,481,599

10,200,236

Total liabilities

23,613,226

21,955,213

Equity:

Preferred stock, par value $0.0001; 4,999,999 shares authorized, none are issued and outstanding
   at September 30, 2020 and 5,000,000 shares authorized and none are issued and outstanding
   at June 30, 2020

Special voting preferred stock, par value $0.0001; 1 share authorized, issued and outstanding at
   September 30, 2020 with $1.00 preference in liquidation and none authorized, issued and
   outstanding at June 30, 2020

20,405,219

Common stock, par value $0.0001; 75,000,000 shares authorized, 14,685,932 issued and
   outstanding at September 30, 2020, and 13,258,707 shares issued and outstanding at June 30,
   2020

1,464

1,321

Additional paid-in capital

83,164,840

72,906,924

Accumulated other comprehensive (loss) income

(7,000)

63,000

Accumulated deficit

(45,842,967)

(41,101,091)

Total stockholders’ equity

$

57,721,556

$

31,870,154

Noncontrolling interests in consolidated subsidiary

4,704,252

Total equity

57,721,556

36,574,406

Total liabilities and equity 

$

81,334,782

$

58,529,619

 


AKERNA CORP.


 Condensed Consolidated Statements of Operations


(unaudited)


For the Three Months
Ended


September 30,


2020


2019

Revenues

Software

$

3,154,442

$

2,254,480

Consulting

331,080

831,363

Other

228,482

107,047

Total revenues

3,714,004

3,192,890

Cost of revenues

1,739,937

1,379,701

Gross profit

1,974,067

1,813,189

Operating expenses

Product development

1,758,826

610,902

Sales and marketing

2,097,502

1,841,514

General and administrative

2,470,187

1,742,301

Depreciation and amortization

1,171,022

17,899

Total operating expenses

7,497,537

4,212,616

Loss from operations

(5,523,470)

(2,399,427)

Other income (expense)

Interest (expense), net

(3,687)

73,382

Change in fair value of Convertible Notes

778,000

Other

(287)

Total other income (expense)

774,313

73,095

Net loss before income tax expense

(4,749,157)

(2,326,332)

Equity in losses of investee

(1,534)

Net loss

(4,750,691)

(2,326,332)

Net loss attributable to noncontrolling interest in consolidated subsidiary 

8,815

Net loss attributable to Akerna shareholders

$

(4,741,876)

$

(2,326,332)

Basic and diluted weighted average common stock outstanding

14,058,412

10,879,112

Basic and diluted net loss per common share

$

(0.34)

$

(0.21)

 


AKERNA CORP.

 Condensed Consolidated Statements of Cash Flows


(unaudited)


For the Three Months
Ended


September 30,


2020


2019

Cash flows from operating activities

Net loss

$

(4,750,691)

$

(2,326,332)

Adjustment to reconcile net loss to net cash used in operating activities:

Equity in losses of investment

1,534

Bad debt

12,450

252,809

Stock-based compensation expense

681,419

161,165

Depreciation and amortization

1,171,022

17,899

Foreign currency loss

4,901

Change in fair value of convertible notes

(778,000)

Change in fair value of contingent consideration 

(389,000)

Changes in operating assets and liabilities:

Accounts receivable

(9,298)

(1,508,217)

Prepaid expenses and other current assets

(74,023)

(292,272)

Accounts payable and accrued liabilities

(296,802)

274,566

Deferred revenue

245,329

278,208

Net cash used in operating activities

(4,181,159)

(3,142,174)

Cash flows from investing activities

Developed software additions

(624,863)

(519,739)

FF&E additions

(12,203)

Cash paid for business combination, net of cash acquired

(5,067,740)

Net cash used in investing activities

(5,704,806)

(519,739)

Cash flows from financing activities

Cash paid for deferred stock offering costs

(12,668)

Cash received in connection with exercise of warrants

4,242,454

Net cash (used in) provided by financing activities

(12,668)

4,242,454

  Effect of exchange rate changes on cash and restricted cash

663

Net change in cash and restricted cash

(9,897,970)

580,541

Cash and restricted cash – beginning of period

24,655,828

22,367,289

Cash and restricted cash – end of period

$

14,757,858

$

22,947,830

 


AKERNA CORP.



Non-GAAP Measures


For the Three Months Ended September 30, 2020 and 2019


Earnings Before Interest, Taxes, Depreciation
and Amortization and Adjusted EBITDA 


2020


2019

Net loss

$

(4,750,691)

$

(2,326,332)

Adjustments:

Interest (income) expense and change in fair value of convertible notes

(774,313)

(73,382)

Depreciation and amortization

1,171,022

17,899

EBITDA

$

(4,353,982)

$

(2,381,815)

Stock-based compensation expense

681,419

161,165

Business combination and merger related costs

951,865

Debt issuance costs related to fair value option debt instruments

43,167

Restructuring charges

68,190

Changes in fair value of contingent consideration

(389,000)

Equity in losses of investee

1,534

 Adjusted EBITDA

$

(2,996,807)

$

(2,220,650)

 


Non-GAAP Operating Expense


2020


2019

Operating expenses                                                                                       

$ 7,497,537

$ 4,212,616

Adjustments:

Depreciation and amortization

1,171,022

17,899

Stock-based compensation expense

663,708

148,652

Business combination and merger related costs

951,865

Debt issuance costs

43,167

Restructuring charges

68,190

Changes in fair value of contingent consideration

(389,000)

Non-GAAP operating expenses

4,988,585

4,046,065

Ample Organics total operating expense

1,319,850

Total operating expenses non-GAAP excluding Ample

$ 3,668,735

$ 4,046,065

 


Non-GAAP Product Development Expense


2020


2019

 Product development expenses

$     1,758,826

$   610,902

 Adjustments:

 Stock-based compensation expense

183,214

45,046

 Non-GAAP product development expenses

1,575,612

565,856

Ample Organics product development expense

592,740

Total product development expenses non-GAAP excluding Ample               

$        982,872

$   565,856

 


AKERNA CORP.


Non-GAAP Measures


For the Three Months Ended September 30, 2020 and 2019

 


Non-GAAP Sales and Marketing Expense


2020


2019

 Sales and marketing expenses

$     2,097,502

$1,841,514

 Adjustments:

 Stock-based compensation expense

134,435

62,064

 Non-GAAP sales and marketing expenses

1,963,067

1,779,450

Ample Organics sales and marketing expenses

396,572

Total sales and marketing expenses non-GAAP excluding Ample

$     1,566,495

$1,779,450

 


Non-GAAP General and Administrative Expense


2020


2019

 General and administrative expenses

$     2,470,187

$   1,742,301

 Adjustments:

 Stock-based compensation expense

346,059

41,542

 Business combination and merger related costs

951,865

 Debt issuance costs

43,167

 Restructuring charges

68,190

 Changes in fair value of contingent consideration

(389,000)

 Non-GAAP General and administrative expenses

1,449,906

1,700,759

 Ample Organics general and administrative expenses

330,538

Total general and administrative non-GAAP excluding Ample

$     1,119,368

$   1,700,759

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/akerna-corp-reports-quarter-ended-september-2020-results-301171681.html

SOURCE Akerna

Amsterdam University Medical Centers Treats 1,000th Patient with MRIdian SMART MRI-Guided Radiation Therapy

Amsterdam UMC reaches treatment milestone while establishing key clinical evidence in tough-to-treat cancer including pancreas, prostate, lung, liver, and kidney

PR Newswire

CLEVELAND, Nov. 12, 2020 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has treated one thousand patients using MRIdian SMART (stereotactic MR-guided adaptive radiotherapy). Amsterdam UMC continues to advance the practice of high-dose ablative radiation therapy with MRIdian through research and publication of the center’s findings.

Amsterdam UMC began treating patients with MRIdian in 2016 and has been a leader in the treatment of prostate, pancreatic, lung, liver, and kidney cancers. MRIdian SMART allows for high doses of radiation to be delivered over a short course of therapy, given the system’s real-time soft-tissue visualization capabilities and the ability for daily plan adaptation. To date, Amsterdam UMC has published more than a dozen manuscripts on their experience with MRIdian and had more than 50 MRIdian-related abstracts featured at major medical meetings around the world.

Recently, Amsterdam UMC published their experience using MRIdian SMART for the treatment of primary renal cell carcinoma in high-surgical-risk patients, given the system’s ability to deliver a completely non-invasive outpatient ablative treatment. Unlike other therapy options, no fiducials are required when delivering treatment on MRIdian. At 12-month follow-up, there was low toxicity (zero grade ≥3) and high local control (95.2 percent). Findings were particularly noteworthy given that most patients were elderly (mean age was 78.1 years) and some tumors were quite large (tumor diameter ranged from 2.4-9.3 cm; mean 5.6 cm).

Full results, as published in the September 25, 2020 issue of Cancers, are available open access: https://www.mdpi.com/2072-6694/12/10/2763.

Additionally, Amsterdam UMC completed a prospective single arm phase 2 study of SBRT with MRIdian for the treatment of prostate cancer. At 1-year follow-up, the study demonstrated zero grade 3 toxicities and very low grade 2 toxicities in more than 100 patients, of which more than half were high-risk (59.4 percent). This study shows low incidence of early toxicity using MRIdian SMART while eliminating potential complications and costs associated with implanted marker procedures.

“Because MRIdian allows us to utilize smaller uncertainty margins and employ daily adaptive planning, we believe it is well-suited  suited to treat a variety of tough to treat cancers for which high-dose radiation may not typically be considered,” said Prof. Ben Slotman, M.D., Ph.D., FACR, FASTRO, Professor & Chairman, Radiation Oncology Departments Amsterdam UMC. “In prostate cancer specifically, previous data illustrates the quality of life challenges patients can experience after radiation therapy, such as bowel symptoms, whereas we saw very low incidence of early GI and GU toxicity, both in clinician- and patient-reported outcome measurements in our MRIdian SBRT study.”

Final results were published in the June 12, 2020 issue of European Urology Oncology:https://euoncology.europeanurology.com/article/S2588-9311(20)30061-4/fulltext and early toxicity results were published in the December 2019 issue of the International Journal of Radiation Oncology*Biology*Physics: https://www.redjournal.org/article/S0360-3016(19)33640-5/fulltext.

Currently, 40 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. More than 11,000 patients have been treated with MRIdian. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

ViewRay is a medical device manufacturer and cannot and does not recommend specific treatment approaches. Individual results may vary. The results described herein may not be predictive

Conflicts of Interest: Anna M.E. Bruynzeel has received honoraria from ViewRay, Inc. outside of the scope of these studies and has served on the advisory board of ViewRay, Inc. Frank J. Lagerwaard and Miguel A. Palacios have received honoraria from Viewray, Inc. outside of the scope of these studies. Suresh Senan has received research grants from ViewRay, Inc. Berend J. Slotman has received research grants and honoraria from ViewRay Inc.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay’s anticipated future operating and financial performance, and ViewRay’s conference calls to discuss its quarterly results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay’s products, the ability to convert backlog into revenue, the timing of delivery of ViewRay’s products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business in general, see ViewRay’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its Quarterly Reports on Form 10-Q, as updated periodically with the company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/amsterdam-university-medical-centers-treats-1-000th-patient-with-mridian-smart-mri-guided-radiation-therapy-301171563.html

SOURCE ViewRay, Inc.

Ovintiv™ Names Brendan M. McCracken as President

PR Newswire

DENVER, Colo., Nov. 12, 2020 /PRNewswire/ – Ovintiv Inc. (NYSE: OVV) (TSX: OVV) today named Brendan M. McCracken as president, effective December 1, 2020.

“Today’s appointment recognizes Brendan’s significant impact on our success and reflects our confidence in his leadership,” said CEO Doug Suttles. “This move is part of our ongoing executive development and ensures that we have leaders for the future.” 

McCracken will maintain his current responsibilities of investor relations, external affairs and strategy and reporting to him will be the COO; EVP, midstream, marketing and fundamentals; and the EVP, corporate services. No senior leadership positions are being added with this announcement.

McCracken has more than two decades of experience in a variety of operational and commercial roles in the oil and natural gas sector. He is an active member of the American Petroleum Institute, the Canadian Association of Petroleum Producers, the Association of Professional Engineers & Geoscientists of Alberta and the Dean’s Advisory Council to the Mount Royal University Faculty of Business and Communications. McCracken graduated from Queen’s University with a bachelor of science degree in mechanical engineering and holds an MBA from the University of Oxford.

About Ovintiv Inc.

Ovintiv is one of the largest producers of oil, condensate and natural gas in North America. The Company is committed to preserving its financial strength, maximizing profitability through disciplined capital investments and operational efficiencies and returning capital to shareholders. A talented team, in combination with a culture of innovation and efficiency, fuels our economic performance, increases shareholder value and strengthens our commitment to sustainability in the communities where we live and work. To learn more, visit:  www.ovintiv.com

Further information on Ovintiv Inc. is available on the Company’s website, www.ovintiv.com, or by contacting:

Investor contact: (888) 525- 0304
Media contact: (281) 210-5253

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ovintiv-names-brendan-m-mccracken-as-president-301171520.html

SOURCE Ovintiv Inc.